Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Elisa Passini, a postdoctoral research assistant from the Computational Cardiovascular Science group, which is part of CRE, has officially been awarded the 2017 international prize from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs).

The £30k award, which is sponsored by GSK, was presented to Elisa in London on the evening of 12th March 2018, by Sir Mark Walport, the Chief Executive Designate of UK Research and Innovation.

Awarded annually, the NC3Rs prize highlights an outstanding and original contribution to scientific and technological advances in the 3Rs. 

The 2017 award recognised Elisa's research with colleagues and Janssen Pharmacaeutica, conducted in Professor Blanca Rodriguez and Dr Alfonso Bueno-Orovio’s group at the University of Oxford’s Department of Computer Science, on an in silico model that predicts cardiotoxicity more accurately than animal studies. 

The winning paper, published in Frontiers in Physiology, describes a drug trial, where 62 drugs and reference compounds were tested at various concentrations in more than a thousand simulations of human heart cells; the computer model predicted risk with 89% accuracy, whereas previous studies on animals had shown 75% accuracy. 

Early predictions of possible heart problems is massively important for drug development, given that 40% of drugs withdrawn from the market between 2001 and 2010 had cardiovascular safety issues. 

Estimates suggest that more than 60,00 animals are used globally to asses drug risk to cardiac safety, and so computational models such as that developed by Elisa and her colleagues could reduce this number dramatically. 

You can hear Elisa's thoughts on winning the award in the video below.


Similar stories

Genetic breakthrough to target care for deadly heart condition

CRE Research

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.

Two major BHF awards to Neil Herring pave the way to new treatments for heart attack patients

CRE Research

Associate Professor Neil Herring has been awarded a Senior Clinical Research Fellowship and a Project grant from the British Heart Foundation to further critical research into the mechanisms behind heart attacks and heart failure and potential drugs to combat them. Given the 50% reduction in research investment this year from the BHF due to the impact of COVID-19, Prof Herring is to be congratulated on these awards.